Ascentage Pharma to Present at Investor Conferences
Ticker: AAPG · Form: 6-K · Filed: Oct 30, 2025 · CIK: 2023311
Sentiment: neutral
Topics: investor-relations, conference-participation, foreign-private-issuer
TL;DR
Ascentage Pharma (001-42484) is hitting up two investor conferences in Nov '25.
AI Summary
Ascentage Pharma Group International announced on October 29, 2025, that it will participate in two investor conferences in November 2025. The company, located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China, is a foreign private issuer filing a Form 6-K report.
Why It Matters
Participation in investor conferences can signal management's confidence and provide updates on company progress, potentially influencing investor sentiment and stock valuation.
Risk Assessment
Risk Level: low — This filing is an announcement of participation in conferences, not a material financial event.
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer of the report
- October 29, 2025 (date) — Date of press release issuance
- November 2025 (date) — Month of investor conference participation
- 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China (location) — Company's principal executive offices
- 001-42484 (other) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is to report a press release issued by Ascentage Pharma Group International on October 29, 2025, announcing its participation in two upcoming investor conferences in November 2025.
When was the press release announcing the conference participation issued?
The press release was issued on October 29, 2025.
Where are Ascentage Pharma Group International's principal executive offices located?
Ascentage Pharma Group International's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Which form does Ascentage Pharma Group International file annual reports under?
Ascentage Pharma Group International files annual reports under Form 20-F.
What is the Commission File Number for Ascentage Pharma Group International?
The Commission File Number for Ascentage Pharma Group International is 001-42484.
Filing Stats: 198 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-10-30 08:30:03
Filing Documents
- ea0263035-6k_ascentage.htm (6-K) — 11KB
- ea026303501ex99-1_ascentage.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001213900-25-103798.txt ( ) — 50KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On October 29, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report. INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated October 29, 2025 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: October 30, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 2